LAURA：同步/序贯放化疗后奥希替尼在 III 期 EGFR 突变 NSCLC
类型: 论文 发表日期: 2024-06-02 入库日期: 2026-05-21 来源: NEJM / PubMed 标签: EGFR L858R, 奥希替尼, LAURA, 局部晚期, 放化疗
Citation
Lu S, Kato T, Dong X, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. New England Journal of Medicine. 2024. DOI: 10.1056/NEJMoa2402614
Why this is in CCL
Mom is stage IV rather than unresectable stage III, so this is not directly applicable. It is still useful background because it shows how strongly osimertinib has moved across EGFR-mutated NSCLC stages and helps frame questions about local therapy plus systemic EGFR control.
Key takeaways
- Population: unresectable stage III EGFR-mutated NSCLC without progression after chemoradiotherapy.
- Strategy: osimertinib maintenance after definitive CRT.
- Relevance is contextual, especially when discussing local control of oligoprogressive lesions.
Practical relevance
- Do not use as direct evidence for metastatic maintenance decisions.
- Keep as background for radiation/local-control discussions, especially if doctors consider treating selected progressing lesions while maintaining systemic therapy.
Update — June 2026: LAURA 安全性详细数据（ASCO 2026 后续发表）
来源： Kato T, Dong X, Takahashi T, et al. Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study. ASCO 2026 / OncoDaily (2026-06-09).
新增安全性数据：
| 不良事件 | 奥希替尼组 | 安慰剂组 |
|---|---|---|
| 放射性肺炎（任意级别） | 48% | 38% |
| 放射性肺炎（≥3级） | 少见（多数1–2级） | — |
| 继续用药率（出现放射性肺炎后） | 87% | — |
| 放射性肺炎无复发率 | 93% | — |
临床含义： 奥希替尼联合放化疗后放射性肺炎风险略高（48% vs 38%），但绝大多数为低级别，可管理，87% 患者在肺炎出现后仍能继续奥希替尼治疗。这一数据为妈妈理解放疗 + 靶向联合背景下的肺毒性管理提供了参考。
注： 妈妈是 IV 期而非 III 期，本安全性数据仍属间接参考，不影响当前治疗方案决策。